Clinical Trials Logo

Clinical Trial Summary

The overall goal of this SBIR Phase II project is to reduce cancer rates by marketing a brief, easily implemented technology-based intervention that increases human papillomavirus (HPV) vaccination among Planned Parenthood and other clients. The intervention's innovative technology allows for the investigators' narrative videos to be presented along will reminder texts. It will be evaluated for use in waiting rooms and promises to overcome vaccination barriers among high risk but underserved low SES and minority populations.


Clinical Trial Description

The purpose of this Phase II research project is to evaluate and market an innovative health message intervention to increase uptake of the human papillomavirus (HPV) vaccine and reduce women's cervical cancer risk through partnership with Planned Parenthood. The overall aim is to reach a broad population through Planned Parenthood, the nation's leading sexual and reproductive health care center, especially among low socioeconomic status (SES) and historically underserved populations. Despite an overall increase in vaccination and reduction in HPV-related infections in younger populations targeted by previous health promotion efforts, young adult women who are recommended for vaccination demonstrate much lower vaccination rates and higher rates of infection. In a recent Phase I grant, the investigators developed and demonstrated the usability and feasibility of an innovative, culturally-grounded, technology-based narrative intervention that delivers decision narratives in the form of videos via a health kiosk, an underutilized communication strategy for reaching less involved audiences. This brief, low-cost, easily implementable intervention doubled the uptake of the vaccine in a separate pilot study. The proposed Phase II project will: (1) Complete development of the intervention, (2) Evaluate its effectiveness through a randomized clinical trial, and (3) Prepare the product for the market. To accomplish these aims, the investigators will develop the intervention for implementation in waiting rooms as part of check-in procedures. Development includes programming and installing tablets to accomplish these tasks (Aim 1). The investigators will then conduct the evaluation study in four Planned Parenthood clinics in southeastern Pennsylvania (Aim 2). Eligible women will be consented, complete a pretest, and then randomized to view the brief intervention or attention control messages via the tablet. After viewing the messages, the participants will complete a short posttest. Treatment participants will receive follow up texts/emails as reminders to vaccinate, and all participants will receive texts/emails with links that allow completion of posttest surveys at 3- and 9 months. Finally, the investigators will prepare the intervention for the market that includes not only Planned Parenthood but other clinics that are currently served by the project partners as well as the broader market for HPV vaccination (Aim 3). In summary, the proposed communication strategy has wide reaching implications not only for reducing cancer risk, but more broadly for designing brief and easily implemented prevention messages across many domains of public health. The research will also close the health disparities gap in minority, under-served young adult women's access to preventive health care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03497936
Study type Interventional
Source Real Prevention, LLC
Contact Michael L Hecht, Ph.D.
Phone 8143601893
Email hechtpsu@gmail.com
Status Not yet recruiting
Phase N/A
Start date May 1, 2018
Completion date September 30, 2018

See also
  Status Clinical Trial Phase
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Recruiting NCT03604393 - Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise N/A
Recruiting NCT03404310 - Zinc Sulfate for Human Papillomavirus (HPV) N/A
Recruiting NCT03302858 - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Phase 2
Completed NCT03082950 - HPV Infections, Cancer of the Vulva and Therapeutical Success
Recruiting NCT03729518 - TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck Phase 2
Recruiting NCT01487681 - Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China N/A
Recruiting NCT03351855 - HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV Phase 1/Phase 2
Recruiting NCT03439085 - Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers Phase 2
Withdrawn NCT01663558 - Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Phase 4
Completed NCT01461408 - Promoting Human Papillomavirus (HPV) Vaccination Through African American Beauty Salons N/A
Completed NCT00730704 - Acceptance of Human Papillomavirus Vaccination in Postpartum Women N/A
Recruiting NCT02072148 - The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) N/A
Recruiting NCT01806714 - Text Reminders to Immunize in a Managed Care Organization N/A
Completed NCT01304966 - Human Papillomatosis Genotyping of Children in Thailand N/A
Recruiting NCT03162224 - Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer Phase 1/Phase 2
Completed NCT03186430 - PreTeenVax Evaluation N/A
Recruiting NCT03734003 - Infrared Bioeffect System for the Treatment of Cutaneous Warts N/A
Active, not recruiting NCT03139669 - Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators N/A
Terminated NCT01221753 - Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study Phase 2